EMEA-003046-PIP01-21
Key facts
| Active substance |
Alnuctamab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0421/2021
|
| PIP number |
EMEA-003046-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of mature B cell malignancies
|
| Route(s) of administration |
|
| Contact for public enquiries |
Bristol-Myers Squibb International Corporation
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|